2,739 Shares in Edwards Lifesciences Corporation $EW Acquired by Valued Retirements Inc.

Valued Retirements Inc. bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,739 shares of the medical research company’s stock, valued at approximately $214,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Econ Financial Services Corp purchased a new stake in Edwards Lifesciences during the second quarter valued at about $889,000. Randolph Co Inc acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $301,000. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,760,000. Arkadios Wealth Advisors acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $300,000. Finally, Mirova US LLC grew its position in Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Robert W. Baird set a $83.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. UBS Group restated a “neutral” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Jefferies Financial Group set a $98.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Barclays reissued an “overweight” rating and set a $99.00 target price (up from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Trading Down 0.0%

Edwards Lifesciences stock opened at $86.74 on Monday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.40. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $50.34 billion, a PE ratio of 12.48, a PEG ratio of 3.97 and a beta of 1.03. The business’s 50-day simple moving average is $79.93 and its 200-day simple moving average is $78.48.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.